Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor ... Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.08 | 3.4188034188 | 2.34 | 2.56 | 2.095 | 1895433 | 2.30632627 | CS |
| 4 | -0.75 | -23.6593059937 | 3.17 | 3.31 | 2.095 | 1698609 | 2.38844741 | CS |
| 12 | 0.28 | 13.0841121495 | 2.14 | 3.39 | 1.67 | 1572920 | 2.35551106 | CS |
| 26 | 0.24 | 11.0091743119 | 2.18 | 3.39 | 1.67 | 1368836 | 2.32955294 | CS |
| 52 | 0.12 | 5.21739130435 | 2.3 | 11.48 | 1.67 | 2018442 | 4.17082669 | CS |
| 156 | -14.89 | -86.0196418255 | 17.31 | 47.2508 | 1.67 | 1223019 | 11.51119206 | CS |
| 260 | -16.23 | -87.0241286863 | 18.65 | 47.2508 | 1.67 | 1160422 | 11.6190194 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
